Drugs / STAMULUMAB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00563810 | Oct 2004 → Apr 2006 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00104078 | Feb 2005 → Jan 2007 | Becker muscular dystrophy, facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STAMULUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108051 ↗ |
| Known as | Estamulumab | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108051 ↗ |
| Known as | MYO-029 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00563810 ↗ |
| Action | Inhibit | “Growth/differentiation factor 8 inhibitor” CHEMBL2108051 ↗ |
| Modality | Monoclonal antibody | — CHEMBL2108051 ↗ |
| Route | Intravenous | “Administered Intravenously as a 30-Minute Infusion” NCT00563810 ↗ |
| Target | MSTN | “Growth/differentiation factor 8 inhibitor” CHEMBL2108051 ↗ |